Cardiovascular Disease — Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Citation(s)
Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13;160(5):685-93.
Bertrand ME Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004 Oct;20(10):1559-69. Review.
Dao HH, Essalihi R, Bouvet C, Moreau P Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005 May 1;66(2):307-17. Review.
Darne B, Girerd X, Safar M, Cambien F, Guize L Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension. 1989 Apr;13(4):392-400.
Djamali A, Sadowski E, Muehrer R, et al Losartan Improves Renal Medullary Oxygenation and Oxidative Stress in Patients with Chronic Allograft Nephropathy. J.Am.Soc.Nephrol. 15 (Abstract Issue):SA-PO1026, 2004
Ferrari AU, Radaelli A, Centola M Invited review: aging and the cardiovascular system. J Appl Physiol (1985). 2003 Dec;95(6):2591-7. Review.
Hallan S, Asberg A, Lindberg M, Johnsen H Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004 Jul;44(1):84-93.
Kundhal K, Lok CE Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract. 2005;101(2):c47-52. Epub 2005 Jun 7. Review.
Lloyd-Jones DM, Evans JC, Levy D Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005 Jul 27;294(4):466-72.
London GM, Marchais SJ, Guerin AP Arterial stiffness and function in end-stage renal disease. Adv Chronic Kidney Dis. 2004 Apr;11(2):202-9. Review.
Matsuda H, Hayashi K, Saruta T Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens. 2003 Apr;17(4):271-6.
Touyz RM The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003 Apr;5(2):155-64. Review.
Unger T Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J Renin Angiotensin Aldosterone Syst. 2001 Sep;2 Suppl 2:S4-7. Review.
Wang MC, Tsai WC, Chen JY, Huang JJ Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005 Mar;45(3):494-501.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
